Nectar Lifesciences Board Approves Q1 FY27 Unaudited Results

Nectar Lifesciences Limited's Board of Directors, in a meeting held on August 14, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also appointed Dr. Gunmala Suri as an Additional Director and Non-Executive Non-Independent Director, subject to member approval. The 31st Annual General Meeting (AGM) is scheduled for September 18, 2026, with the register of members closing from September 12 to September 18. Mr. Sanjiv Goyal will be re-appointed as a director retiring by rotation. Committee compositions for Audit, SRC, and CSR were also reconstituted.